Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients

Keyphrases

• Hispanic 100%
• Cost-effectiveness 100%
• Kidney Transplant Recipients 100%
• Once-daily 100%
• Twice-daily Tacrolimus 100%
• Immediate-release Tacrolimus 100%
• Hispanic Population 33%
• Serious Adverse Events 33%
• Treatment-related 33%
• Graft Failure 33%
• First Year 16%
• Direct Costs 16%
• Black Men 16%
• Phase III Clinical Trial 16%
• Hispanic Patients 16%
• Overall Effectiveness 16%
• Decision-analytic Model 16%
• Patient Demographics 16%
• Twice Daily 16%
• Dialysis 16%
• Overall Cost 16%
• Immunosuppressive Therapy 16%
• Biopsy-proven Rejection 16%
• Tacrolimus 16%
• Identified Parameters 16%
• Prolonged-release Tacrolimus 16%
• Payer Perspective 16%
• Metabolizer 16%
• Rejection Treatment 16%
• Probabilistic Sensitivity Analysis 16%
• One-way Sensitivity Analysis 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Tacrolimus 100%
• Adverse Event 22%
• Graft Failure 22%
• Clinical Trial 11%
• Immunosuppressive Agent 11%
• Tablet 11%
• Acute Graft Rejection 11%